Regeneron touts success with bispecific antibody in multiple myeloma trial [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
The data from the Phase I/II LINKER-MM1 (NCT03761108) study was presented at the European Hematology Association (EHA) Congress 2024 in Madrid, Spain, on 13–16 June. The 14-month follow up data demonstrated a 71% objective response rate, with 50% of patients achieving a complete response or better and 63% achieving a very good partial response or better, as determined by an independent review committee. However, the trial failed to meet key secondary endpoints, including median progression-free survival, median overall survival and median duration of response. Linvoseltamab is a BCMA and CD3-targeting bispecific antibody. It was developed using Regeneron's VelociGene and VelocImmune platform technology. In an interview with Clinical Trials Arena, Suzanne Lentzsch, a trial investigator, highlighted that this treatment offers convenience compared with other bispecific antibody therapies. “In contrast to the currently existing treatments, where [a patient] stays five or eight da
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Will Bristol Myers Squibb Stock Rebound To Its 2022 Highs Of $80? [Forbes]Forbes
- Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Cramer's Lightning Round: ‘I would not abandon' Cava [CNBC]CNBC
- Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Cell and Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15.5% by 2034: Visiongain [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 4/25/24 - Miss
BMY
Sec Filings
- 6/25/24 - Form 11-K
- 6/25/24 - Form 11-K
- 6/25/24 - Form 11-K
- BMY's page on the SEC website